This is a Validated Antibody Database (VAD) review about human CD28, based on 178 published articles (read how Labome selects the articles), using CD28 antibody in all methods. It is aimed to help Labome visitors find the most suited CD28 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD28 synonym: Tp44

Invitrogen
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 5 ug/ml; loading ...; fig 7h
Invitrogen CD28 antibody (Thermo Fisher, 16-0289) was used in blocking or activating experiments on human samples at 5 ug/ml (fig 7h). J Exp Med (2022) ncbi
mouse monoclonal (CD28.6)
  • flow cytometry; mouse
Invitrogen CD28 antibody (eBioscience, 16-0288-85) was used in flow cytometry on mouse samples . iScience (2022) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3a
Invitrogen CD28 antibody (eBioscience, 48-0289-42) was used in flow cytometry on human samples (fig 3a). Immunity (2021) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml; loading ...; fig 1s3a
Invitrogen CD28 antibody (eBioscience, 16-0289-81) was used in blocking or activating experiments on human samples at 1 ug/ml (fig 1s3a). elife (2021) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 4
Invitrogen CD28 antibody (Invitrogen, CD28.1) was used in flow cytometry on human samples (fig 4). Aging Cell (2021) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 4a
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig 4a). BMC Immunol (2020) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 5s1f, 5s1e
Invitrogen CD28 antibody (Life Technologies, LS17028941) was used in flow cytometry on human samples (fig 5s1f, 5s1e). elife (2019) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 2 ug/ml; loading ...; fig 4a
Invitrogen CD28 antibody (eBioscience, 16-0289-85) was used in blocking or activating experiments on human samples at 2 ug/ml (fig 4a). Diagn Pathol (2019) ncbi
mouse monoclonal (CD28.2)
  • immunoprecipitation; human; loading ...; fig 6f
Invitrogen CD28 antibody (Thermo Fisher, 16-0289-85) was used in immunoprecipitation on human samples (fig 6f). Cell Rep (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3a
Invitrogen CD28 antibody (ebioscience, 16-0289-81) was used in flow cytometry on human samples (fig 3a). Oncotarget (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 1 ug/ml; fig 2c
In order to study the involvement of RANKL in decidual M2 macrophage polarization, Invitrogen CD28 antibody (ebioscience, 16-0289) was used in flow cytometry on human samples at 1 ug/ml (fig 2c). Cell Death Dis (2017) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; tbl 1
In order to investigate infiltrating T cells in liver cancer through single-cell sequencing, Invitrogen CD28 antibody (eBioscience, 16-0289-85) was used in blocking or activating experiments on human samples (tbl 1). Cell (2017) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; mouse; loading ...; fig 6e
In order to clarify the mechanisms by which miR-21 contributes to oncogenesis, Invitrogen CD28 antibody (eBioscience, 16-0289-85) was used in blocking or activating experiments on mouse samples (fig 6e). Oncogene (2017) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml; loading ...; fig s9
In order to find neoantigens in human mantle-cell lymphomas using samples from human patients, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples at 1 ug/ml (fig s9). Nature (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig s2
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig s2). Oncoimmunology (2017) ncbi
mouse monoclonal (CD28.6)
  • immunocytochemistry; human; tbl 1
In order to discuss methods to visualize gangliosides involved in CD4 positive T cell activation, Invitrogen CD28 antibody (eBioscience, 16-0288-81) was used in immunocytochemistry on human samples (tbl 1). J Vis Exp (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 6b
In order to define the contribution of CD103+ tumor-infiltrating lymphocytes to high-grade serous epithelial ovarian cancer, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig 6b). Oncotarget (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 5c
In order to identify RLTPR in patients and determine the effects of these mutations on CD4 positive T cells, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig 5c). J Exp Med (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 6a
In order to develop a method to quantify both the spatial distribution of a protein and its colocalization status, Invitrogen CD28 antibody (eBiosciences, 16-0289) was used in blocking or activating experiments on human samples (fig 6a). Mol Biol Cell (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 1
Invitrogen CD28 antibody (eBioscience, 16-0289) was used in blocking or activating experiments on human samples (fig 1). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml; loading ...; fig s3a
In order to use knockout mice to determine the role of cereblon in T cells, Invitrogen CD28 antibody (eBiosciences, CD28.2) was used in blocking or activating experiments on human samples at 1 ug/ml (fig s3a). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 1
Invitrogen CD28 antibody (eBioscience, 28.2) was used in blocking or activating experiments on human samples (fig 1). Oncotarget (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 8
Invitrogen CD28 antibody (eBioscience, 16-0289-85) was used in blocking or activating experiments on human samples (fig 8). J Exp Med (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 5
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig 5). Sci Rep (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; fig 4
In order to assess the ability of HIV-1 envelope glycoprotein-specific broadly neutralizing monoclonal antibodies to suppress acute simian-human immunodeficiency virus replication in rhesus macaques, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 4). J Virol (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 1
Invitrogen CD28 antibody (eBioscience, 16-0289-85) was used in blocking or activating experiments on human samples (fig 1). MAbs (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml; fig 6c
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples at 1 ug/ml (fig 6c). Nat Immunol (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 3
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples (fig 3). Cancer Immunol Res (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml
Invitrogen CD28 antibody (eBIoscience, CD28.2) was used in blocking or activating experiments on human samples at 1 ug/ml. J Biol Chem (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
In order to examine the mechanism of anti-alpha4 antibody treatment in monkeys, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on rhesus macaque samples . PLoS Pathog (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples . J Autoimmun (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on rhesus macaque samples . J Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on rhesus macaque samples . J Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
In order to developed a strategy to expand umbilical cord blood T cells and test their effects after transplantation, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples . Leukemia (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples . J Infect Dis (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples . J Immunol Res (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 2
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig 2). PLoS ONE (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
In order to examine human differentiated effector CD4(+) T cells that are defined by low levels of IL-2 and IL-7 receptors, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rat
In order to determine the effect of aging and CMV infection on T cell populations, Invitrogen CD28 antibody (eBioscience, 13-0289) was used in flow cytometry on rat samples . J Immunol (2014) ncbi
mouse monoclonal (CD28.6)
  • neutralization; human
In order to investigate the effect of mechanical force on the T cell receptor, Invitrogen CD28 antibody (eBioscience, 16-0288) was used in neutralization on human samples . Proc Natl Acad Sci U S A (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml
In order to test the effect of different Mycobacterium tuberculosis molecules on HIV-1 replication, Invitrogen CD28 antibody (Ebioscience, CD28.2) was used in blocking or activating experiments on human samples at 1 ug/ml. PLoS ONE (2013) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...
In order to use Tat, Env, and Tat/Env regimens to induce and immune response and then assess protective efficacy using clade C Env, alum adjuvant, and a heterologous intrarectal SHIV1157ipd3N4 challenge, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on rhesus macaque samples . Virology (2013) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...; fig 2a
In order to test if vaccination alters the activation state of T cells within the gastrointestinal mucosa, inguinal lymph nodes, and peripheral blood, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 2a). Hum Vaccin Immunother (2012) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
In order to analyze the regulation of Amphiregulin expression in human T cell subsets, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples . PLoS ONE (2012) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig S4A
In order to examine tumor and nonadjacent normal breast tissue from women with breast cancer, who either had or had not received neoadjuvant chemotherapy before surgery, Invitrogen CD28 antibody (eBioscience, 25-0289-42) was used in flow cytometry on human samples (fig S4A). Proc Natl Acad Sci U S A (2012) ncbi
mouse monoclonal (10F3)
  • flow cytometry; mouse; fig 3
In order to compare the therapeutic efficacy of CD19-specific human primary T cells that constitutively express gamma(c)-cytokines, Invitrogen CD28 antibody (Caltag, 10F3) was used in flow cytometry on mouse samples (fig 3). Blood (2010) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 3
In order to show that surface IL-17A is a marker for Th17 cells, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on human samples (fig 3). J Immunol (2009) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 1
In order to investigate how anti-CD3 monoclonal antibodies alter human immune responses in type 1 diabetes, Invitrogen CD28 antibody (Caltag, CD28.2) was used in flow cytometry on human samples (fig 1). Clin Immunol (2010) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; crab eating macaque
  • flow cytometry; rhesus macaque
In order to assess PD-1 expression on CD3 positive T cells after DNA vaccination or lentiviral infection of macaques, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in flow cytometry on crab eating macaque samples and in flow cytometry on rhesus macaque samples . Eur J Immunol (2008) ncbi
mouse monoclonal (10F3)
  • blocking or activating experiments; human
In order to determine the relationship between organophosphate pesticide exposure and biomarkers of oxidative stress and DNA damage, Invitrogen CD28 antibody (Invitrogen, 10F3) was used in blocking or activating experiments on human samples . Toxicol Appl Pharmacol (2008) ncbi
mouse monoclonal (10F3)
  • blocking or activating experiments; human; 0.2 ug/ml; fig 3c
In order to generate a selectable lentiviral vector with a proliferative advantage to study transgene immunogenicity in gene-modified T cells, Invitrogen CD28 antibody (Caltag/Invitrogen, 10F3) was used in blocking or activating experiments on human samples at 0.2 ug/ml (fig 3c). Gene Ther (2007) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
In order to assess the T cell-stimulatory capacity of mature dendritic cells and macrophages using a model of allogeneic MLR, Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples . J Immunol (2006) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
In order to determine the frequency, phenotype, and function of peripheral CD4+ CD8+ T cells in rhesus macaques infected with simian immunodeficiency virus, Invitrogen CD28 antibody (Caltag, CD28.2) was used in flow cytometry on rhesus macaque samples . Immunology (2006) ncbi
mouse monoclonal (CD28.6)
  • blocking or activating experiments; human; 15 ug/ml
Invitrogen CD28 antibody (eBioscience, CD28.6) was used in blocking or activating experiments on human samples at 15 ug/ml. J Immunol (2006) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 0.1 ug/ml
Invitrogen CD28 antibody (eBioscience, CD28.2) was used in blocking or activating experiments on human samples at 0.1 ug/ml. J Immunol (2006) ncbi
BioLegend
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 2b
BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples (fig 2b). Proc Natl Acad Sci U S A (2022) ncbi
mouse monoclonal (CD28.2)
  • mass cytometry; human; loading ...; fig s4a
BioLegend CD28 antibody (Biolegend, 302937) was used in mass cytometry on human samples (fig s4a). Biomark Res (2022) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 5e
BioLegend CD28 antibody (Biolegend, 302902) was used in flow cytometry on human samples (fig 5e). Cell (2021) ncbi
mouse monoclonal (CD28.2)
  • mass cytometry; human; 1:50; loading ...; fig s2
BioLegend CD28 antibody (Biolegend, CD28.2) was used in mass cytometry on human samples at 1:50 (fig s2). Int J Mol Sci (2021) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig s3-3d
BioLegend CD28 antibody (Biolegend, 302910) was used in flow cytometry on human samples (fig s3-3d). elife (2020) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 1:50; loading ...
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples at 1:50. Sci Signal (2020) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 1b
BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples (fig 1b). Sci Rep (2019) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3a
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 3a). Cell Stem Cell (2019) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 1a
BioLegend CD28 antibody (Biolegend, CD28.2) was used in blocking or activating experiments on human samples (fig 1a). Eur J Immunol (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig s2e
BioLegend CD28 antibody (BioLegend, 302920) was used in flow cytometry on human samples (fig s2e). Cell (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 5c
BioLegend CD28 antibody (Biolegend, 28.2) was used in flow cytometry on human samples (fig 5c). J Immunol (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 2c
BioLegend CD28 antibody (Biolegend, 28.2) was used in flow cytometry on human samples (fig 2c). Sci Rep (2017) ncbi
mouse monoclonal (CD28.2)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend CD28 antibody (BioLegend, CD28.2) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 2c
BioLegend CD28 antibody (Biolegend, CD28.2) was used in blocking or activating experiments on human samples (fig 2c). Oncotarget (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
In order to find a role for IL-4 in promoting breast cancer aggressiveness, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples . Cancer Res (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig s1e
In order to use CD49a expression to define subsets of tissue-resident memory T cells in the skin, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig s1e). Immunity (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...; fig 4b
In order to study CXCR5+ CD8 T cells in SIV-infected animals, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 4b). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig s6b
In order to assess whether human T-cell leukemia virus type 1 bZIP factor enhances the proliferation of expressing T cells after stimulation via the T-cell receptor, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples (fig s6b). PLoS Pathog (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 1b
In order to characterize gammadelta T cell subsets from healthy humans, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 1b). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig s4a
In order to study the contribution of T follicular helper cells to islet autoimmunity, BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples (fig s4a). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; fig 4a
In order to examine the contribution of HIV-derived conserved elements in vaccination, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 4a). J Immunol (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig s1
BioLegend CD28 antibody (Biolegend, 28.2) was used in flow cytometry on human samples (fig s1). PLoS Pathog (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 2b
In order to suggest that the BRD4-p300 signaling cascade promotes antitumor T cell grafts that could be used adoptive immunotherapy, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples (fig 2b). J Clin Invest (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 4
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 4). J Immunol Res (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...
In order to generate a T-cell receptor-like monoclonal antibody (8F4) that binds the PR1/HLA-A2 complex and test it in preclinical models of acute myeloid leukemia, BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Cytotherapy (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 1
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 1). Sci Rep (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 5 ug/ml; loading ...; fig s2
BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples at 5 ug/ml (fig s2). Anesthesiology (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 2
BioLegend CD28 antibody (BioLegend, 302902) was used in flow cytometry on human samples (fig 2). Nat Biotechnol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 1a
In order to characterize innate lymphoid cell subpopulations isolated from patients with systemic sclerosis, BioLegend CD28 antibody (biolegend, CD28.2) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 3
BioLegend CD28 antibody (BioLegend, 28.2) was used in blocking or activating experiments on human samples (fig 3). J Immunol Methods (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
In order to present the role of M-sec in polarized secretion of inflammatory endothelial chemokines and CCL2-mediated lymphocyte transendothelial migration, BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . J Leukoc Biol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 1
In order to assess the CD4/CD8 ratio as a marker for CD4+ T cell dysfunction in chronic HIV infection, BioLegend CD28 antibody (Biolegend, clone CD28.2) was used in flow cytometry on human samples (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
BioLegend CD28 antibody (Biolegend, 302906) was used in flow cytometry on human samples . Cytometry A (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 7
BioLegend CD28 antibody (Biolegend, CD28.2) was used in blocking or activating experiments on human samples (fig 7). Nat Commun (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; tbl 2
BioLegend CD28 antibody (BioLegend, 302934) was used in blocking or activating experiments on human samples (tbl 2). Immunol Lett (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 6
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples (fig 6). Cancer Res (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Cell Signal (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 3
In order to compare five SIV vaccine platforms, BioLegend CD28 antibody (BioLegend, clone CD28.2) was used in flow cytometry on human samples (fig 3). Clin Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Arch Immunol Ther Exp (Warsz) (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
In order to examine the effect of HMBPP-deficient Listeria mutant immunization, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on rhesus macaque samples . J Leukoc Biol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 1 ug/ml
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples at 1 ug/ml. Med Microbiol Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
In order to compare vaccination with highly conserved gag elements verses full-length gag DNA, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on rhesus macaque samples . PLoS ONE (2014) ncbi
Miltenyi Biotec
mouse monoclonal (15E8)
  • blocking or activating experiments; human; 0.5 ug/ml; loading ...; fig 2b
Miltenyi Biotec CD28 antibody (Miltenyi Biotec, 130-093-375) was used in blocking or activating experiments on human samples at 0.5 ug/ml (fig 2b). PLoS ONE (2022) ncbi
mouse monoclonal (15E8)
  • blocking or activating experiments; human; 1,000 ug/ml; loading ...
Miltenyi Biotec CD28 antibody (Miltenyi Biotec, 130-093-375) was used in blocking or activating experiments on human samples at 1,000 ug/ml. Cell (2019) ncbi
Bio X Cell
mouse monoclonal (CD28.2)
  • immunocytochemistry; human; loading ...; fig 3c
Bio X Cell CD28 antibody (Bio X Cell, BE0291) was used in immunocytochemistry on human samples (fig 3c). Immunity (2019) ncbi
mouse monoclonal (9.3)
  • blocking or activating experiments; human; loading ...; fig 3
In order to assess the role of glycogen synthase kinase-3 in the production of IL-10 by CD4 positive T helper cells, Bio X Cell CD28 antibody (BioXCell, 9.3) was used in blocking or activating experiments on human samples (fig 3). Eur J Immunol (2015) ncbi
mouse monoclonal (9.3)
  • blocking or activating experiments; human; loading ...; fig 3b
Bio X Cell CD28 antibody (BioXCell, 9.3) was used in blocking or activating experiments on human samples (fig 3b). J Immunol (2015) ncbi
Santa Cruz Biotechnology
hamsters monoclonal (PV-1)
  • western blot; human
Santa Cruz Biotechnology CD28 antibody (Santa Cruz Biotechnology, PV-1) was used in western blot on human samples . Mol Cell Biol (2014) ncbi
Abcam
hamsters monoclonal (PV-1)
  • western blot; human
In order to describe a method to generate bispecific antibodies, Abcam CD28 antibody (Abcam, ab25234) was used in western blot on human samples . Nat Commun (2015) ncbi
Beckman Coulter
mouse monoclonal (CD28.2)
  • flow cytometry; African green monkey; loading ...; fig 1a
  • flow cytometry; rhesus macaque; loading ...; fig 1a
Beckman Coulter CD28 antibody (Beckman Coulter, 6607111) was used in flow cytometry on African green monkey samples (fig 1a) and in flow cytometry on rhesus macaque samples (fig 1a). J Clin Invest (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...; fig s8a
In order to examine the kinetics of SIV-specific CD8+ T cell cytolytic factor expression in peripheral blood, lymph node, spleen, and gut mucosa from early acute infection through chronic infection, Beckman Coulter CD28 antibody (Beckman Coulter, CD28.2) was used in flow cytometry on rhesus macaque samples (fig s8a). PLoS Pathog (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...; fig 2a
In order to report the effect of IL-15 inhibition on T and natural killer cell dynamics in rhesus macaques, Beckman Coulter CD28 antibody (Beckman Coulter, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 2a). J Immunol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...
In order to optimize vaccination with Aventis Pasteur's canarypox vector-HIV, Beckman Coulter CD28 antibody (Beckman Coulter, 6607111) was used in flow cytometry on rhesus macaque samples . Nat Med (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 2
Beckman Coulter CD28 antibody (Beckman-Coulter, IM1376) was used in blocking or activating experiments on human samples (fig 2). Oncol Lett (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
In order to describe a selective CD28 antagonist for treatment of rheumatoid arthritis, Beckman Coulter CD28 antibody (Beckman Coulter, CD282) was used in flow cytometry on rhesus macaque samples . Clin Exp Immunol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; fig 4
In order to elucidate how CD8 positive T cells suppress virus replication during simian immunodeficiency virus infection, Beckman Coulter CD28 antibody (Beckman Coulter, 28.2) was used in flow cytometry on rhesus macaque samples (fig 4). J Virol (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 0.2 ug/ml; fig 1
Beckman Coulter CD28 antibody (Beckman Coulter, CD28.2) was used in flow cytometry on human samples at 0.2 ug/ml (fig 1). J Autoimmun (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; tbl s5
In order to investigate when Vgamma9Vdelta2 T cells develop, Beckman Coulter CD28 antibody (Beckman Coulter, CD28.2) was used in flow cytometry on human samples (tbl s5). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
Beckman Coulter CD28 antibody (Beckman Coulter, 6607111) was used in flow cytometry on rhesus macaque samples . J Virol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
Beckman Coulter CD28 antibody (Beckman Coulter, CD28.2) was used in flow cytometry on rhesus macaque samples . Antimicrob Agents Chemother (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque
Beckman Coulter CD28 antibody (Beckman Coulter, CD28.2) was used in flow cytometry on rhesus macaque samples . J Immunol (2014) ncbi
Exbio
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3a
Exbio CD28 antibody (Exbio, CD28.2) was used in flow cytometry on human samples (fig 3a). J Virol (2018) ncbi
BD Biosciences
mouse monoclonal (CD28.2)
  • flow cytometry; mouse; 1:200; loading ...; fig 1c, 7a
BD Biosciences CD28 antibody (BD Biosciences, 562613) was used in flow cytometry on mouse samples at 1:200 (fig 1c, 7a). Cancer Res (2021) ncbi
mouse monoclonal (L293)
  • flow cytometry; human; 1:10; loading ...; fig 2s1
BD Biosciences CD28 antibody (BD Biosciences, 348047) was used in flow cytometry on human samples at 1:10 (fig 2s1). elife (2020) ncbi
mouse monoclonal (L293)
  • blocking or activating experiments; human; 1 ug/ml; loading ...; fig 2d
BD Biosciences CD28 antibody (BD Biosciences, 340975) was used in blocking or activating experiments on human samples at 1 ug/ml (fig 2d). elife (2020) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 1f
BD Biosciences CD28 antibody (BD Biosciences, 556620) was used in blocking or activating experiments on human samples (fig 1f). elife (2020) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples . J Immunother Cancer (2020) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 4d
BD Biosciences CD28 antibody (BD, CD28.2) was used in flow cytometry on human samples (fig 4d). PLoS Pathog (2019) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3b
BD Biosciences CD28 antibody (BD Biosciences, 555729) was used in flow cytometry on human samples (fig 3b). Cell Rep (2019) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 4a
BD Biosciences CD28 antibody (BD, CD28.2) was used in blocking or activating experiments on human samples (fig 4a). J Exp Med (2019) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 1b
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples (fig 1b). Eur J Immunol (2019) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...; fig 1f
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 1f). J Virol (2019) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3
BD Biosciences CD28 antibody (BD, 559770) was used in flow cytometry on human samples (fig 3). J Virol (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 2
BD Biosciences CD28 antibody (BD, CD28.2) was used in flow cytometry on human samples (fig 2). Biol Blood Marrow Transplant (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...
BD Biosciences CD28 antibody (BD Bioscience, CD28.2) was used in flow cytometry on human samples . J Immunol (2017) ncbi
mouse monoclonal (L293)
  • blocking or activating experiments; human; loading ...; fig 1a
In order to detail MAIT cell responses to various microorganisms and cytokines, BD Biosciences CD28 antibody (BD Biosciences, L293) was used in blocking or activating experiments on human samples (fig 1a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 4a
In order to demonstrate that PD-1 inhibits T cell function primarily by inactivating CD28 signaling, BD Biosciences CD28 antibody (BD, 555729) was used in flow cytometry on human samples (fig 4a). Science (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 3e
BD Biosciences CD28 antibody (BD Biosciences, 559770) was used in flow cytometry on human samples (fig 3e). Oncoimmunology (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 2d
In order to assess the functional role of IL-31 in basophil biology, BD Biosciences CD28 antibody (BD Bioscience, CD28.2) was used in blocking or activating experiments on human samples (fig 2d). Clin Exp Allergy (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...
In order to develop a functional assay to assess the risk of developing acute graft-versus-host disease, BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples . J Immunol Res (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; mouse; 2 ug/ml; loading ...; fig s7a
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in blocking or activating experiments on mouse samples at 2 ug/ml (fig s7a). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 2 ug/ml; loading ...; fig s5
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in blocking or activating experiments on human samples at 2 ug/ml (fig s5). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; tbl 3
BD Biosciences CD28 antibody (BD Pharmingen, CD28.2) was used in flow cytometry on human samples (tbl 3). Brain Behav (2016) ncbi
mouse monoclonal (L293)
  • flow cytometry; human; loading ...; fig 5a
In order to explore signaling pathways regulated by RLTPR in T and B cells, BD Biosciences CD28 antibody (BD, L293) was used in flow cytometry on human samples (fig 5a). J Exp Med (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; loading ...; fig 1a
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on rhesus macaque samples (fig 1a). J Virol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; rhesus macaque; tbl 1
In order to characterize the role of T-cell depletion and macrophage polarization and infection during splenic damage during SIV infection, BD Biosciences CD28 antibody (BD, CD28.2) was used in flow cytometry on rhesus macaque samples (tbl 1). Am J Pathol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig s2d
BD Biosciences CD28 antibody (BD, CD28.2) was used in flow cytometry on human samples (fig s2d). J Clin Invest (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; mouse; loading ...; fig st1
BD Biosciences CD28 antibody (BD Pharmingen, CD28.2) was used in flow cytometry on mouse samples (fig st1). J Clin Invest (2016) ncbi
mouse monoclonal (L293)
  • flow cytometry; African green monkey; loading ...; fig s2
In order to discuss the use of flow cytometry to examine common marmosets, BD Biosciences CD28 antibody (BD, L 293) was used in flow cytometry on African green monkey samples (fig s2). J Med Primatol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...
In order to study the role of T regulatory cells in patients with immune thrombocytopenic purpura, BD Biosciences CD28 antibody (BD Pharmingen, 555728) was used in flow cytometry on human samples . Turk J Haematol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 5
In order to test if the two hematopoietic systems in patients with mixed chimerism remain functional and study immunological differences, BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples (fig 5). PLoS ONE (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 4
BD Biosciences CD28 antibody (BD Pharmigen, 555725) was used in blocking or activating experiments on human samples (fig 4). Sci Rep (2016) ncbi
mouse monoclonal (L293)
  • flow cytometry; human; loading ...; fig 2a
In order to demonstrate that effector T-cell accumulation and TCR repertoire diversity reduction precede the development of foot ulcers in diabetic patients, BD Biosciences CD28 antibody (BD, L293) was used in flow cytometry on human samples (fig 2a). Cell Mol Immunol (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences CD28 antibody (BD, 555729) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 1
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples (fig 1). Oncoimmunology (2016) ncbi
mouse monoclonal (L293)
  • flow cytometry; rhesus macaque; loading ...; fig 5c
In order to study the CD8+ non-cytolytic antiviral response in SIV infected rhesus macaques, BD Biosciences CD28 antibody (BD Biosciences, L293) was used in flow cytometry on rhesus macaque samples (fig 5c). PLoS ONE (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1.25 ug/ml; fig 2
In order to elucidate mechanisms that regulate T cell glycolytic metabolism, BD Biosciences CD28 antibody (BD Bioscience, CD28.2) was used in blocking or activating experiments on human samples at 1.25 ug/ml (fig 2). Nat Immunol (2016) ncbi
mouse monoclonal (L293)
  • blocking or activating experiments; human; fig s6
In order to study the use of bispecific T cell engager, BD Biosciences CD28 antibody (BD Biosciences, L293) was used in blocking or activating experiments on human samples (fig s6). PLoS ONE (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; mouse; fig 1c
BD Biosciences CD28 antibody (BD Biosciences, 555725) was used in blocking or activating experiments on mouse samples (fig 1c). Nat Commun (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 2
BD Biosciences CD28 antibody (BD Biosciences, 560685) was used in flow cytometry on human samples (fig 2). Retrovirology (2015) ncbi
mouse monoclonal (L293)
  • blocking or activating experiments; human; 2.5 ug/ml; fig 1
  • western blot; human; 2.5 ug/ml; fig 1
In order to assess JNK-dependent alternative splicing in T-cell activation through CELF2-mediated regulation of MKK7, BD Biosciences CD28 antibody (BD Biosciences, 348040) was used in blocking or activating experiments on human samples at 2.5 ug/ml (fig 1) and in western blot on human samples at 2.5 ug/ml (fig 1). Genes Dev (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
In order to study T cell subtypes in breast cancer patients with and without high levels of autoimmune thyroid antibodies, BD Biosciences CD28 antibody (BD Pharmingen, 555728) was used in flow cytometry on human samples . Cent Eur J Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 7d
In order to investigate the role of VAMP8 in exocytosis, BD Biosciences CD28 antibody (BD, CD28.2) was used in blocking or activating experiments on human samples (fig 7d). J Cell Biol (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 1:20
BD Biosciences CD28 antibody (BD Biosciences, 563075) was used in flow cytometry on human samples at 1:20. Nat Commun (2015) ncbi
mouse monoclonal (L293)
  • flow cytometry; rhesus macaque
BD Biosciences CD28 antibody (BD Biosciences, L293) was used in flow cytometry on rhesus macaque samples . Vaccine (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; tbl 4
In order to discuss how to diagnosis hematolymphoid neoplasms using flow cytometry, BD Biosciences CD28 antibody (BD Bioscience, CD28.2) was used in flow cytometry on human samples (tbl 4). Cytometry B Clin Cytom (2015) ncbi
mouse monoclonal (L293)
  • other; human; fig 2
In order to characterize capabilities and potentials of extracellular vesicle (EV) array, BD Biosciences CD28 antibody (BD Biosciences, 340975) was used in other on human samples (fig 2). J Extracell Vesicles (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 7
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples (fig 7). PLoS ONE (2015) ncbi
mouse monoclonal (L293)
  • blocking or activating experiments; human; fig s3
BD Biosciences CD28 antibody (BD Pharmingen, 348040) was used in blocking or activating experiments on human samples (fig s3). EMBO Mol Med (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 2.5 ug/ml
BD Biosciences CD28 antibody (BD Pharmingen, CD28.2) was used in flow cytometry on human samples at 2.5 ug/ml. Mol Immunol (2015) ncbi
mouse monoclonal (CD28.2)
  • immunohistochemistry; mouse; 1:300
In order to examine the role of TLR7 in HIV-infected CD4 positive T cells, BD Biosciences CD28 antibody (BD, 28.2) was used in immunohistochemistry on mouse samples at 1:300. Nat Immunol (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml; fig 2
BD Biosciences CD28 antibody (BD Pharmingen, 555725) was used in blocking or activating experiments on human samples at 1 ug/ml (fig 2). Mol Cell Biol (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples . Rheumatology (Oxford) (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; baboons; fig 1
In order to study the effect of age, gender, social status and peer group on T cells in baboons, BD Biosciences CD28 antibody (Becton-Dickinson, clone CD28.2) was used in flow cytometry on baboons samples (fig 1). PLoS ONE (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
BD Biosciences CD28 antibody (BD, CD28.2) was used in flow cytometry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
In order to study the role of CD93 molecule in mature dendritic cells and T cells, BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in blocking or activating experiments on human samples . Immunobiology (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 1 ug/ml
In order to study the effect of atorvastatin on telomerase activity in peripheral blood mononuclear cells and T-lymphocytes, BD Biosciences CD28 antibody (BD, 555725) was used in blocking or activating experiments on human samples at 1 ug/ml. Atherosclerosis (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 5 ug/ml
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in blocking or activating experiments on human samples at 5 ug/ml. J Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
BD Biosciences CD28 antibody (BD Biosciences, CD28.2) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (L293)
  • blocking or activating experiments; human; 1 ug/ml
In order to examine the function of NK- and T-cells in order to understand how chronic myeloid leukemia patients maintain the treatment response after IFN-alpha discontinuation, BD Biosciences CD28 antibody (BD, L293) was used in blocking or activating experiments on human samples at 1 ug/ml. PLoS ONE (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 5 ug/ml
In order to show that CKIP-1 interacts with CARMA1 and inhibits PKCtheta-CBM-NF-kappaB signaling, BD Biosciences CD28 antibody (BD, 555725) was used in blocking or activating experiments on human samples at 5 ug/ml. PLoS ONE (2014) ncbi
mouse monoclonal (L293)
  • flow cytometry; human
In order to examine the effect on cellular iron uptake upon expression of the accessory protein Nef from different lentiviral strains, BD Biosciences CD28 antibody (BD, L293) was used in flow cytometry on human samples . Retrovirology (2014) ncbi
mouse monoclonal (CD28.2)
  • immunocytochemistry; human; 5 ug/ml
BD Biosciences CD28 antibody (BD Pharmingen, 555725) was used in immunocytochemistry on human samples at 5 ug/ml. Mol Cell Biol (2013) ncbi
Articles Reviewed
  1. Laffey K, Stiles R, Ludescher M, Davis T, Khwaja S, Bram R, et al. Early expression of mature αβ TCR in CD4-CD8- T cell progenitors enables MHC to drive development of T-ALL bearing NOTCH mutations. Proc Natl Acad Sci U S A. 2022;119:e2118529119 pubmed publisher
  2. Hickman T, Choi E, Whiteman K, Muralidharan S, Pai T, Johnson T, et al. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS ONE. 2022;17:e0266980 pubmed publisher
  3. Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, et al. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022;10:13 pubmed publisher
  4. Liu M, Wu C, Luo S, Hua Q, Chen H, Weng Y, et al. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. J Exp Med. 2022;219: pubmed publisher
  5. Sibilio A, Suñer C, Fernández Alfara M, Martín J, Berenguer A, Calon A, et al. Immune translational control by CPEB4 regulates intestinal inflammation resolution and colorectal cancer development. iScience. 2022;25:103790 pubmed publisher
  6. Nathan A, Rossin E, Kaseke C, Park R, Khatri A, Koundakjian D, et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021;: pubmed publisher
  7. West J, Austin E, Rizzi E, Yan L, Tanjore H, Crabtree A, et al. KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models. Int J Mol Sci. 2021;22: pubmed publisher
  8. Szabo P, Dogra P, Gray J, Wells S, Connors T, Weisberg S, et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. 2021;54:797-814.e6 pubmed publisher
  9. Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra Avila N, Carreño L, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788-1801 pubmed publisher
  10. Lafouresse F, Jugele R, Müller S, Doineau M, Duplan Eche V, Espinosa E, et al. Stochastic asymmetric repartition of lytic machinery in dividing CD8+ T cells generates heterogeneous killing behavior. elife. 2021;10: pubmed publisher
  11. Webb L, Fra Bido S, Innocentin S, Matheson L, Attaf N, Bignon A, et al. Ageing promotes early T follicular helper cell differentiation by modulating expression of RBPJ. Aging Cell. 2021;20:e13295 pubmed publisher
  12. Neidleman J, Luo X, Frouard J, Xie G, Hsiao F, Ma T, et al. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. elife. 2020;9: pubmed publisher
  13. Gunesch J, Dixon A, Ebrahim T, Berrien Elliott M, Tatineni S, Kumar T, et al. CD56 regulates human NK cell cytotoxicity through Pyk2. elife. 2020;9: pubmed publisher
  14. Zurli V, Montecchi T, Heilig R, Poschke I, Volkmar M, Wimmer G, et al. Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Sci Signal. 2020;13: pubmed publisher
  15. Liu G, Yu Y, Feng F, Zhu P, Zhang H, Zhang D, et al. Human CD8+CD28- T suppressor cells expanded by common gamma chain (γc) cytokines retain steady allospecific suppressive capacity in vivo. BMC Immunol. 2020;21:23 pubmed publisher
  16. Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille Reece U, et al. A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses. elife. 2020;9: pubmed publisher
  17. Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, et al. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife. 2020;9: pubmed publisher
  18. Marotte L, Simon S, Vignard V, Dupré E, Gantier M, Cruard J, et al. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes. J Immunother Cancer. 2020;8: pubmed publisher
  19. Zhao Y, Lee C, Lin C, Gassen R, Xu X, Huang Z, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019;51:1059-1073.e9 pubmed publisher
  20. Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8: pubmed publisher
  21. Banga R, Rebecchini C, Procopio F, Noto A, Munoz O, Ioannidou K, et al. Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. PLoS Pathog. 2019;15:e1007918 pubmed publisher
  22. Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher
  23. Han L, Hu J, Ma B, Wen D, Zhang T, Lu Z, et al. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. Diagn Pathol. 2019;14:52 pubmed publisher
  24. Fenwick C, Loredo Varela J, Joo V, Pellaton C, Farina A, Rajah N, et al. Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. J Exp Med. 2019;: pubmed publisher
  25. Humeniuk P, Geiselhart S, Battin C, Webb T, Steinberger P, Paster W, et al. Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor. Sci Rep. 2019;9:7426 pubmed publisher
  26. Remmerswaal E, Hombrink P, Nota B, Pircher H, ten Berge I, van Lier R, et al. Expression of IL-7Rα and KLRG1 defines functionally distinct CD8+ T-cell populations in humans. Eur J Immunol. 2019;49:694-708 pubmed publisher
  27. Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango M, Kaufmann S, et al. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell. 2019;: pubmed publisher
  28. Montel Hagen A, Seet C, Li S, Chick B, Zhu Y, Chang P, et al. Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells. Cell Stem Cell. 2019;24:376-389.e8 pubmed publisher
  29. Hoang T, Harper J, Pino M, Wang H, Micci L, King C, et al. Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir. J Virol. 2019;93: pubmed publisher
  30. Fischer M, Bantug G, Dimeloe S, Gubser P, Burgener A, Grählert J, et al. Early effector maturation of naïve human CD8+ T cells requires mitochondrial biogenesis. Eur J Immunol. 2018;48:1632-1643 pubmed publisher
  31. Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher
  32. Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge S, et al. Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2. J Virol. 2018;92: pubmed publisher
  33. Ferrando Martinez S, Moysi E, Pegu A, Andrews S, Nganou Makamdop K, Ambrozak D, et al. Accumulation of follicular CD8+ T cells in pathogenic SIV infection. J Clin Invest. 2018;128:2089-2103 pubmed publisher
  34. Shi Y, Zhang P, Wang G, Liu X, Sun X, Zhang X, et al. Description of organ-specific phenotype, and functional characteristics of tissue resident lymphocytes from liver transplantation donor and research on immune tolerance mechanism of liver. Oncotarget. 2018;9:15552-15565 pubmed publisher
  35. Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher
  36. Hutten T, Norde W, Woestenenk R, Wang R, Maas F, Kester M, et al. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018;24:666-677 pubmed publisher
  37. Moreno Cubero E, Subira D, Sanz de Villalobos E, Parra Cid T, Madejon A, Miquel J, et al. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity. J Virol. 2018;92: pubmed publisher
  38. Meng Y, Zhou W, Jin L, Liu L, Chang K, Mei J, et al. RANKL-mediated harmonious dialogue between fetus and mother guarantees smooth gestation by inducing decidual M2 macrophage polarization. Cell Death Dis. 2017;8:e3105 pubmed publisher
  39. Salio M, Gasser O, González López C, Martens A, Veerapen N, Gileadi U, et al. Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. J Immunol. 2017;199:2631-2638 pubmed publisher
  40. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed publisher
  41. Zhang X, Lian X, Dai Z, Zheng H, Chen X, Zheng Y. ?3-Deletion Isoform of HLA-A11 Modulates Cytotoxicity of NK Cells: Correlations with HIV-1 Infection of Cells. J Immunol. 2017;199:2030-2042 pubmed publisher
  42. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  43. Dias J, Leeansyah E, Sandberg J. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114:E5434-E5443 pubmed publisher
  44. Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169:1342-1356.e16 pubmed publisher
  45. Domae E, Hirai Y, Ikeo T, Goda S, Shimizu Y. Cytokine-mediated activation of human ex vivo-expanded V?9V?2 T cells. Oncotarget. 2017;8:45928-45942 pubmed publisher
  46. Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77:3268-3279 pubmed publisher
  47. He W, Wang C, Mu R, Liang P, Huang Z, Zhang J, et al. MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles. Oncogene. 2017;36:4212-4223 pubmed publisher
  48. Khodadoust M, Olsson N, Wagar L, Haabeth O, Chen B, Swaminathan K, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017;543:723-727 pubmed publisher
  49. Hui E, Cheung J, Zhu J, Su X, Taylor M, Wallweber H, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428-1433 pubmed publisher
  50. Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang S, Marquardt N, et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. Immunity. 2017;46:287-300 pubmed publisher
  51. Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2017;6:e1249558 pubmed publisher
  52. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop H, Rooney C, et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5:e1253656 pubmed publisher
  53. Mylvaganam G, Rios D, Abdelaal H, Iyer S, Tharp G, Mavigner M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A. 2017;114:1976-1981 pubmed publisher
  54. Kinosada H, Yasunaga J, Shimura K, Miyazato P, Onishi C, Iyoda T, et al. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog. 2017;13:e1006120 pubmed publisher
  55. Roberts E, Carnathan D, Li H, Shaw G, Silvestri G, Betts M. Collapse of Cytolytic Potential in SIV-Specific CD8+ T Cells Following Acute SIV Infection in Rhesus Macaques. PLoS Pathog. 2016;12:e1006135 pubmed publisher
  56. Raap U, Gehring M, Kleiner S, Rüdrich U, Eiz Vesper B, Haas H, et al. Human basophils are a source of - and are differentially activated by - IL-31. Clin Exp Allergy. 2017;47:499-508 pubmed publisher
  57. Sairafi D, Stikvoort A, Gertow J, Mattsson J, Uhlin M. Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. J Immunol Res. 2016;2016:5601204 pubmed
  58. Morita K, Okamura T, Inoue M, Komai T, Teruya S, Iwasaki Y, et al. Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production. Proc Natl Acad Sci U S A. 2016;113:E8131-E8140 pubmed
  59. Ryan P, Sumaria N, Holland C, Bradford C, Izotova N, Grandjean C, et al. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc Natl Acad Sci U S A. 2016;113:14378-14383 pubmed
  60. Villanueva Cabello T, Martinez Duncker I. Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy. J Vis Exp. 2016;: pubmed publisher
  61. Peters C, Häsler R, Wesch D, Kabelitz D. Human Vδ2 T cells are a major source of interleukin-9. Proc Natl Acad Sci U S A. 2016;113:12520-12525 pubmed
  62. Serr I, Fürst R, Ott V, Scherm M, Nikolaev A, Gökmen F, et al. miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A. 2016;113:E6659-E6668 pubmed
  63. Dyer W, Tan J, Day T, Kiers L, Kiernan M, Yiannikas C, et al. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain Behav. 2016;6:e00516 pubmed
  64. Hu X, Valentin A, Dayton F, Kulkarni V, Alicea C, Rosati M, et al. DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. J Immunol. 2016;197:3999-4013 pubmed
  65. Komdeur F, Wouters M, Workel H, Tijans A, Terwindt A, Brunekreeft K, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130-75144 pubmed publisher
  66. Jung Y, Riven I, Feigelson S, Kartvelishvily E, Tohya K, Miyasaka M, et al. Three-dimensional localization of T-cell receptors in relation to microvilli using a combination of superresolution microscopies. Proc Natl Acad Sci U S A. 2016;113:E5916-E5924 pubmed
  67. Wang Y, Ma C, Ling Y, Bousfiha A, Camcioglu Y, Jacquot S, et al. Dual T cell- and B cell-intrinsic deficiency in humans with biallelic RLTPR mutations. J Exp Med. 2016;213:2413-2435 pubmed
  68. Roncagalli R, Cucchetti M, Jarmuzynski N, Gregoire C, Bergot E, Audebert S, et al. The scaffolding function of the RLTPR protein explains its essential role for CD28 co-stimulation in mouse and human T cells. J Exp Med. 2016;213:2437-2457 pubmed
  69. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  70. Pageon S, Nicovich P, Mollazade M, Tabarin T, Gaus K. Clus-DoC: a combined cluster detection and colocalization analysis for single-molecule localization microscopy data. Mol Biol Cell. 2016;27:3627-3636 pubmed
  71. Pageon S, Tabarin T, Yamamoto Y, Ma Y, Nicovich P, Bridgeman J, et al. Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proc Natl Acad Sci U S A. 2016;113:E5454-63 pubmed publisher
  72. Ayala V, Trivett M, Barsov E, Jain S, Piatak M, Trubey C, et al. Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques. J Virol. 2016;90:9942-9952 pubmed publisher
  73. Kagoya Y, Nakatsugawa M, Yamashita Y, Ochi T, Guo T, Anczurowski M, et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016;126:3479-94 pubmed publisher
  74. Kang J, Park S, Jeong S, Han M, Lee C, Lee K, et al. Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation. Proc Natl Acad Sci U S A. 2016;113:8771-6 pubmed publisher
  75. DeGottardi M, Okoye A, Vaidya M, Talla A, Konfe A, Reyes M, et al. Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques. J Immunol. 2016;197:1183-98 pubmed publisher
  76. Williams D, Engle E, Shirk E, Queen S, Gama L, Mankowski J, et al. Splenic Damage during SIV Infection: Role of T-Cell Depletion and Macrophage Polarization and Infection. Am J Pathol. 2016;186:2068-2087 pubmed publisher
  77. Heath J, Newhook N, Comeau E, Gallant M, Fudge N, Grant M. NKG2C(+)CD57(+) Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8(+) T Cell Evolution towards Senescence. J Immunol Res. 2016;2016:7470124 pubmed publisher
  78. Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa L, Rodgers J, et al. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest. 2016;126:2678-88 pubmed publisher
  79. Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, et al. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016;126:2588-96 pubmed publisher
  80. Ma Q, Garber H, Lu S, He H, Tallis E, Ding X, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016;18:985-94 pubmed publisher
  81. Hahn S, Neuhoff A, Landsberg J, Schupp J, Eberts D, Leukel P, et al. A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget. 2016;7:42996-43009 pubmed publisher
  82. van der Heiden M, van Zelm M, Bartol S, de Rond L, Berbers G, Boots A, et al. Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. Sci Rep. 2016;6:26892 pubmed publisher
  83. Vaccari M, Gordon S, Fourati S, Schifanella L, Liyanage N, Cameron M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016;22:762-70 pubmed publisher
  84. Neumann B, Shi T, Gan L, Klippert A, Daskalaki M, Stolte Leeb N, et al. Comprehensive panel of cross-reacting monoclonal antibodies for analysis of different immune cells and their distribution in the common marmoset (Callithrix jacchus). J Med Primatol. 2016;45:139-46 pubmed publisher
  85. Akyol Erikci A, Karagoz B, Bilgi O. Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. Turk J Haematol. 2016;33:153-5 pubmed publisher
  86. Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, et al. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS ONE. 2016;11:e0154737 pubmed publisher
  87. Maki Y, Nishimura Y, Toyooka S, Soh J, Tsukuda K, Shien K, et al. The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells. Oncol Lett. 2016;11:3308-3316 pubmed
  88. Kumar A, Abbas W, Colin L, Khan K, Bouchat S, Varin A, et al. Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line. Sci Rep. 2016;6:24090 pubmed publisher
  89. Moura J, Rodrigues J, Goncalves M, Amaral C, Lima M, Carvalho E. Impaired T-cell differentiation in diabetic foot ulceration. Cell Mol Immunol. 2017;14:758-769 pubmed publisher
  90. van der Heide V, Möhnle P, Rink J, Briegel J, Kreth S. Down-regulation of MicroRNA-31 in CD4+ T Cells Contributes to Immunosuppression in Human Sepsis by Promoting TH2 Skewing. Anesthesiology. 2016;124:908-22 pubmed publisher
  91. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  92. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, et al. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology. 2016;5:e1104448 pubmed
  93. Hu H, Wang H, Xiao Y, Jin J, Chang J, Zou Q, et al. Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. J Exp Med. 2016;213:399-414 pubmed publisher
  94. Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell S. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol. 2016;34:430-4 pubmed publisher
  95. Roan F, Stoklasek T, Whalen E, Molitor J, Bluestone J, Buckner J, et al. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016;196:2051-2062 pubmed publisher
  96. Su S, Hu B, Shao J, Shen B, Du J, Du Y, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070 pubmed publisher
  97. Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher
  98. Barzilai S, Blecher Gonen R, Barnett Itzhaki Z, Zauberman A, Lebel Haziv Y, Amit I, et al. M-sec regulates polarized secretion of inflammatory endothelial chemokines and facilitates CCL2-mediated lymphocyte transendothelial migration. J Leukoc Biol. 2016;99:1045-55 pubmed publisher
  99. Bolton D, Pegu A, Wang K, McGinnis K, Nason M, Foulds K, et al. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. J Virol. 2016;90:1321-32 pubmed publisher
  100. Javed A, Leuchte N, Neumann B, Sopper S, Sauermann U. Noncytolytic CD8+ Cell Mediated Antiviral Response Represents a Strong Element in the Immune Response of Simian Immunodeficiency Virus-Infected Long-Term Non-Progressing Rhesus Macaques. PLoS ONE. 2015;10:e0142086 pubmed publisher
  101. Vierboom M, Breedveld E, Kap Y, Mary C, Poirier N, t Hart B, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol. 2016;183:405-18 pubmed publisher
  102. Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2016;17:95-103 pubmed publisher
  103. Deisting W, Raum T, Kufer P, Baeuerle P, Münz M. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE. 2015;10:e0141669 pubmed publisher
  104. Oh Y, Park H, Shin J, Lee J, Park H, Kho D, et al. Ndrg1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2. Nat Commun. 2015;6:8698 pubmed publisher
  105. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed publisher
  106. Martinez N, Agosto L, Qiu J, Mallory M, Gazzara M, Barash Y, et al. Widespread JNK-dependent alternative splicing induces a positive feedback loop through CELF2-mediated regulation of MKK7 during T-cell activation. Genes Dev. 2015;29:2054-66 pubmed publisher
  107. Frederiksen J, Buggert M, Noyan K, Nowak P, Sönnerborg A, Lund O, et al. Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. PLoS ONE. 2015;10:e0137635 pubmed publisher
  108. Silacci M, Lembke W, Woods R, Attinger Toller I, Baenziger Tobler N, Batey S, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141-9 pubmed publisher
  109. Nakatsukasa H, Zhang D, Maruyama T, Chen H, Cui K, Ishikawa M, et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells. Nat Immunol. 2015;16:1077-84 pubmed publisher
  110. Biylgi O, Karagöz B, Türken O, Gültepe M, Özgün A, Tunçel T, et al. CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients. Cent Eur J Immunol. 2014;39:338-44 pubmed publisher
  111. Marshall M, Pattu V, Halimani M, Maier Peuschel M, Müller M, Becherer U, et al. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J Cell Biol. 2015;210:135-51 pubmed publisher
  112. Mikucki M, Fisher D, Matsuzaki J, Skitzki J, Gaulin N, Muhitch J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458 pubmed publisher
  113. Chowdhury A, Hayes T, Bosinger S, Lawson B, Vanderford T, Schmitz J, et al. Differential Impact of In Vivo CD8+ T Lymphocyte Depletion in Controller versus Progressor Simian Immunodeficiency Virus-Infected Macaques. J Virol. 2015;89:8677-86 pubmed publisher
  114. Soares A, Müller T, Chege G, Williamson A, Burgers W. Transient global T cell activation after vaccination of rhesus macaques with a DNA-poxvirus vaccine regimen for HIV. Vaccine. 2015;33:3435-9 pubmed publisher
  115. Fromm J, Tagliente D, Shaver A, Neppalli V, Craig F. Case study interpretation: Report from the ICCS Annual Meeting, Seattle, 2014. Cytometry B Clin Cytom. 2015;88:413-24 pubmed publisher
  116. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
  117. Rochman Y, Yukawa M, Kartashov A, Barski A. Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS ONE. 2015;10:e0122198 pubmed publisher
  118. Li C, Li W, Xiao J, Jiao S, Teng F, Xue S, et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med. 2015;7:754-69 pubmed publisher
  119. Inglis H, Danesh A, Shah A, Lacroix J, Spinella P, Norris P. Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. Cytometry A. 2015;87:1052-63 pubmed publisher
  120. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692 pubmed publisher
  121. Lin M, Yuan Y, Xu J, Cai X, Liu S, Niu L, et al. Safety and efficacy study of nasopharyngeal cancer stem cell vaccine. Immunol Lett. 2015;165:26-31 pubmed publisher
  122. Nouël A, Pochard P, Simon Q, Ségalen I, Le Meur Y, Pers J, et al. B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. J Autoimmun. 2015;59:53-60 pubmed publisher
  123. Ebsen H, Lettau M, Kabelitz D, Janssen O. Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes. Mol Immunol. 2015;65:416-28 pubmed publisher
  124. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  125. Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. 2015;6:6113 pubmed publisher
  126. Hill E, Ng T, Burton B, Oakley C, Malik K, Wraith D. Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter. Eur J Immunol. 2015;45:1103-15 pubmed publisher
  127. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, et al. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire. Proc Natl Acad Sci U S A. 2015;112:E556-65 pubmed publisher
  128. Chauhan A, Chen C, Moore T, DiPaolo R. Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset. J Biol Chem. 2015;290:5127-40 pubmed publisher
  129. Bushkin Y, Radford F, Pine R, Lardizabal A, Mangura B, Gennaro M, et al. Profiling T cell activation using single-molecule fluorescence in situ hybridization and flow cytometry. J Immunol. 2015;194:836-41 pubmed publisher
  130. Campbell J, Ratai E, Autissier P, Nolan D, Tse S, Miller A, et al. Anti-?4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection. PLoS Pathog. 2014;10:e1004533 pubmed publisher
  131. Caramalho I, Nunes Silva V, Pires A, Mota C, Pinto A, Nunes Cabaço H, et al. Human regulatory T-cell development is dictated by Interleukin-2 and -15 expressed in a non-overlapping pattern in the thymus. J Autoimmun. 2015;56:98-110 pubmed publisher
  132. Li J, Jie H, Lei Y, Gildener Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-518 pubmed publisher
  133. Lugassy J, Corso J, Beach D, Petrik T, Oellerich T, Urlaub H, et al. Modulation of TCR responsiveness by the Grb2-family adaptor, Gads. Cell Signal. 2015;27:125-34 pubmed publisher
  134. Dominguez Villar M, Gautron A, de Marcken M, Keller M, Hafler D. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol. 2015;16:118-28 pubmed publisher
  135. Makowski S, Wang Z, Pomerantz J. A protease-independent function for SPPL3 in NFAT activation. Mol Cell Biol. 2015;35:451-67 pubmed publisher
  136. Fujita T, Burwitz B, Chew G, Reed J, Pathak R, Seger E, et al. Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol. 2014;193:5576-83 pubmed publisher
  137. Jansen D, Hameetman M, van Bergen J, Huizinga T, van der Heijde D, Toes R, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford). 2015;54:728-35 pubmed publisher
  138. Mylvaganam G, Velu V, Hong J, Sadagopal S, Kwa S, Basu R, et al. Diminished viral control during simian immunodeficiency virus infection is associated with aberrant PD-1hi CD4 T cell enrichment in the lymphoid follicles of the rectal mucosa. J Immunol. 2014;193:4527-36 pubmed publisher
  139. Willis E, Eberle R, Wolf R, White G, McFarlane D. The effects of age and cytomegalovirus on markers of inflammation and lymphocyte populations in captive baboons. PLoS ONE. 2014;9:e107167 pubmed publisher
  140. Kudernatsch R, Letsch A, Guerreiro M, Löbel M, Bauer S, Volk H, et al. Human bone marrow contains a subset of quiescent early memory CD8(+) T cells characterized by high CD127 expression and efflux capacity. Eur J Immunol. 2014;44:3532-42 pubmed publisher
  141. Valentin A, McKinnon K, Li J, Rosati M, Kulkarni V, Pilkington G, et al. Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clin Immunol. 2014;155:91-107 pubmed publisher
  142. Matsuda K, Dang Q, Brown C, Keele B, Wu F, Ourmanov I, et al. Characterization of simian immunodeficiency virus (SIV) that induces SIV encephalitis in rhesus macaques with high frequency: role of TRIM5 and major histocompatibility complex genotypes and early entry to the brain. J Virol. 2014;88:13201-11 pubmed publisher
  143. Del Prete G, Shoemaker R, Oswald K, Lara A, Trubey C, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother. 2014;58:6790-806 pubmed publisher
  144. Steiner S, Daniel C, Fischer A, Atreya I, Hirschmann S, Waldner M, et al. Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis. Arch Immunol Ther Exp (Warsz). 2015;63:53-63 pubmed publisher
  145. Kreiser S, Eckhardt J, Kuhnt C, Stein M, Krzyzak L, Seitz C, et al. Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo. Immunobiology. 2015;220:270-9 pubmed publisher
  146. Bennaceur K, Atwill M, Al Zhrany N, Hoffmann J, Keavney B, BREAULT D, et al. Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism. Atherosclerosis. 2014;236:312-20 pubmed publisher
  147. Frencher J, Shen H, Yan L, Wilson J, Freitag N, Rizzo A, et al. HMBPP-deficient Listeria mutant immunization alters pulmonary/systemic responses, effector functions, and memory polarization of Vγ2Vδ2 T cells. J Leukoc Biol. 2014;96:957-67 pubmed publisher
  148. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed publisher
  149. Weist B, Schmueck M, Fuehrer H, Sattler A, Reinke P, Babel N. The role of CD4(+) T cells in BKV-specific T cell immunity. Med Microbiol Immunol. 2014;203:395-408 pubmed publisher
  150. Lee Chang C, Bodogai M, Moritoh K, Olkhanud P, Chan A, Croft M, et al. Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. Blood. 2014;124:1450-9 pubmed publisher
  151. Pegram H, Purdon T, van Leeuwen D, Curran K, Giralt S, Barker J, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415-22 pubmed publisher
  152. Wilson E, Singh A, Hullsiek K, Gibson D, Henry W, Lichtenstein K, et al. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis. 2014;210:1396-406 pubmed publisher
  153. Mao C, Mou X, Zhou Y, Yuan G, Xu C, Liu H, et al. Tumor-activated TCR??? T cells from gastric cancer patients induce the antitumor immune response of TCR??? T cells via their antigen-presenting cell-like effects. J Immunol Res. 2014;2014:593562 pubmed publisher
  154. Cartwright E, McGary C, Cervasi B, Micci L, Lawson B, Elliott S, et al. Divergent CD4+ T memory stem cell dynamics in pathogenic and nonpathogenic simian immunodeficiency virus infections. J Immunol. 2014;192:4666-73 pubmed publisher
  155. Lanteri M, Diamond M, Law J, Chew G, Wu S, Inglis H, et al. Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection. PLoS ONE. 2014;9:e92134 pubmed publisher
  156. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed publisher
  157. Wertheimer A, Bennett M, Park B, Uhrlaub J, Martinez C, Pulko V, et al. Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J Immunol. 2014;192:2143-55 pubmed publisher
  158. Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-? monotherapy. PLoS ONE. 2014;9:e87794 pubmed publisher
  159. Bashour K, Gondarenko A, Chen H, Shen K, Liu X, Huse M, et al. CD28 and CD3 have complementary roles in T-cell traction forces. Proc Natl Acad Sci U S A. 2014;111:2241-6 pubmed publisher
  160. Kulkarni V, Valentin A, Rosati M, Alicea C, Singh A, Jalah R, et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS ONE. 2014;9:e86254 pubmed publisher
  161. Sakamoto T, Kobayashi M, Tada K, Shinohara M, Io K, Nagata K, et al. CKIP-1 is an intrinsic negative regulator of T-cell activation through an interaction with CARMA1. PLoS ONE. 2014;9:e85762 pubmed publisher
  162. Kloog Y, Mor A. Cytotoxic-T-lymphocyte antigen 4 receptor signaling for lymphocyte adhesion is mediated by C3G and Rap1. Mol Cell Biol. 2014;34:978-88 pubmed publisher
  163. Koppensteiner H, H hne K, Gondim M, Gobert F, Widder M, Gundlach S, et al. Lentiviral Nef suppresses iron uptake in a strain specific manner through inhibition of Transferrin endocytosis. Retrovirology. 2014;11:1 pubmed publisher
  164. Rodriguez M, Loyd C, Ding X, Karim A, MCDONALD D, Canaday D, et al. Mycobacterial phosphatidylinositol mannoside 6 (PIM6) up-regulates TCR-triggered HIV-1 replication in CD4+ T cells. PLoS ONE. 2013;8:e80938 pubmed publisher
  165. Demberg T, Brocca Cofano E, Kuate S, Aladi S, Vargas Inchaustegui D, Venzon D, et al. Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology. 2013;440:210-21 pubmed publisher
  166. Moreno Garcia M, Sommer K, Rincón Arano H, Brault M, Ninomiya Tsuji J, Matesic L, et al. Kinase-independent feedback of the TAK1/TAB1 complex on BCL10 turnover and NF-?B activation. Mol Cell Biol. 2013;33:1149-63 pubmed publisher
  167. Reuter M, Yuan S, Marx P, Kutzler M, Weiner D, Betts M. DNA-based HIV vaccines do not induce generalized activation in mucosal tissue T cells. Hum Vaccin Immunother. 2012;8:1648-53 pubmed publisher
  168. Qi Y, Operario D, Georas S, Mosmann T. The acute environment, rather than T cell subset pre-commitment, regulates expression of the human T cell cytokine amphiregulin. PLoS ONE. 2012;7:e39072 pubmed publisher
  169. Ruffell B, Au A, Rugo H, Esserman L, Hwang E, Coussens L. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109:2796-801 pubmed publisher
  170. Markley J, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010;115:3508-19 pubmed publisher
  171. Brucklacher Waldert V, Steinbach K, Lioznov M, Kolster M, Holscher C, Tolosa E. Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. J Immunol. 2009;183:5494-501 pubmed publisher
  172. Cernea S, Herold K. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol. 2010;134:121-9 pubmed publisher
  173. Hokey D, Johnson F, Smith J, Weber J, Yan J, Hirao L, et al. Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol. 2008;38:1435-45 pubmed publisher
  174. Muniz J, McCauley L, Scherer J, Lasarev M, Koshy M, Kow Y, et al. Biomarkers of oxidative stress and DNA damage in agricultural workers: a pilot study. Toxicol Appl Pharmacol. 2008;227:97-107 pubmed
  175. Sangiolo D, Lesnikova M, Nash R, Jensen M, Nikitine A, Kiem H, et al. Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther. 2007;14:1549-54 pubmed
  176. Hoves S, Krause S, Schutz C, Halbritter D, Scholmerich J, Herfarth H, et al. Monocyte-derived human macrophages mediate anergy in allogeneic T cells and induce regulatory T cells. J Immunol. 2006;177:2691-8 pubmed
  177. Macchia I, Gauduin M, Kaur A, Johnson R. Expression of CD8alpha identifies a distinct subset of effector memory CD4+ T lymphocytes. Immunology. 2006;119:232-42 pubmed
  178. Quiroga M, Pasquinelli V, Martinez G, Jurado J, Zorrilla L, Musella R, et al. Inducible costimulator: a modulator of IFN-gamma production in human tuberculosis. J Immunol. 2006;176:5965-74 pubmed